NCT04239092 2025-07-17
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Actuate Therapeutics Inc.
Phase 1 Terminated
Actuate Therapeutics Inc.
Essen Biotech
National Institutes of Health Clinical Center (CC)
Barbara Ann Karmanos Cancer Institute